Skip to main content

Table 1 Baseline characteristics of patients with polypoidal choroidal vasculopathy who were treated with a fixed-dosing intravitreal aflibercept regimen

From: One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient

  All Pre-treated Treatment-naïve P value
Pre-treated vs. Treatment-naïve
Numbers (eyes) 25 13 12  
Age (years) 67.16±8.20 67.2±5.44 67.12±10.7 0.983 a
Sex (male: female) 20: 5 9:4 11:1 0.161b
Laterality (right: left) 15: 10 7:6 8:4 0.513b
Best Corrected Visual acuity
 Snellen 0.53±0.31 0.52±0.33 0.54±0.30 0.841 a
 ETDRS letters 65.48±15.43 64.46±16.52 66.58±14.79 0.739 a
Central macular thickness (μm) 406.92±159.36 356.08±145.58 462±160.99 0.097 a
Location of vascular lesion (eyes)
 Subfoveal 15 (60.0%) 7 (53.8%) 8 (66.6%) 0.566c
 Juxtafoveal 9 (36.0%) 5 (38.5%) 4 (33.3%)
 Extrafoveal 1 (4.0%) 1 (8%) 0 (0%)
Area of branching vascular network (mm2) 3.12±1.98 3.66±2.18 2.11±1.02 0.045a
Numbers of polypoidal lesions 2.60±1.68 3.30±1.88 1.83±1.02 0.025a
Height of the largest polypoidal lesion (μm) 345.64±159.44 331.84±134.21 360.58±187.99 0.662 a
Location of the polyp closest to the foveal center (eyes)
 Subfoveal 11 (44.0%) 3 (23.0%) 8 (66.6%) 0.004c
 Juxtafoveal 7 (28.0%) 3 (23.0%) 4 (33.3%)
 Extrafoveal 7 (28.0%) 7 (53.8%) 0 (0%)
  1. ETDRS Early Treatment of Diabetic Retinopathy Study, a T-test b Chi-squared test) c linear by linear association test
\